United Therapeutics Announces $477.6 Million Accelerated Share Repurchase Agreement

Details

to repurchase approximately $477.6 million of its common stock. This ASR is part of the company's previously announced $2.0 billion share repurchase authorization. The agreement involves an upfront payment by United Therapeutics and an initial delivery of shares based on the closing stock price on September 8, 2026. The final number of shares repurchased will be determined by the average daily volume-weighted average price during the term of the ASR, less a discount. The transaction is expected to be completed in the fourth quarter of 2026. This move is part of the company's strategy to return $4 billion to shareholders over approximately 2.5 years.

Items reported

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company engaged in the development and commercialization of innovative pharmaceutical products. Primarily focusing on therapies to address unmet medical needs for chronic and life-threatening conditions, United Therapeutics is notable for its contributions in the field of pulmonary arterial hypertension (PAH). The company offers a portfolio of products that include both oral and inhaled treatments, such as Remodulin and Tyvaso, providing critical care solutions that significantly improve patients' quality of life. Additionally, they are investing in innovative technologies such as organ manufacturing and regenerative medicine, showcasing a commitment to future medical advances. Headquartered in Silver Spring, Maryland, United Therapeutics operates across various stages of drug research, from clinical trials to post-market analysis. As a key player in the biotechnology industry, the company holds an influential position, contributing to significant advancements in therapeutic solutions and reinforcing its role in the healthcare market by addressing complex medical challenges and patient needs effectively.